We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Gold Nanoparticles Indicate Early Detection of Heart Attacks

By LabMedica International staff writers
Posted on 27 Jan 2015
A test strip for a heart attack biomarker is being developed as its level is several thousand times higher in patients experiencing myocardial infarctions. More...
The new strip uses microplasma technology.

Cardiac troponin I (cTn-I) is a specific marker for myocardial infarction and a new cTn-I test is based on the specific immune-chemical reactions between antigen and antibody on immunochromatographic test strips using gold nanoparticles (AuNPs).

Bioengineers at the New York University Polytechnic School of Engineering used an atmospheric-pressure non-thermal microplasma for the synthesis of aqueous gold nanoparticles (AuNPs). The microplasma-induced liquid chemistry was analyzed by monitoring the pH value and the conductivity of the liquid. A sample pad made of glass fiber was saturated with 100 mM phosphate buffered saline and the anti-cardiac troponin antibody19C7 MAb (HyTest Ltd.; Turku, Finland) was conjugated to AuNPs and sprayed onto the conjugate pad. After the addition of other antibodies, the nitrocellulose membranes were combined with the conjugate pad at the opposite end downstream of the control line. The sample pad was placed on top and in front of the conjugate pad at the site of the sample application wells.

Compared to AuNPs produced by traditional chemical methods, the surfaces of the gold nanoparticles generated by the microplasma-induced liquid chemical process attracted more antibodies, which resulted in significantly higher detection sensitivity. A positive result yields reddish bands at both the test (T) and control (C) positions, whereas a negative result yields a reddish band at position C only. The level of cTn-I is below 0.06 ng/mL in the blood of healthy people, whereas the level of cTn-I may reach 100 ng/mL to 1,300 ng/mL in patients after the onset of acute myocardial infarction (AMI) and remains high for up to four to10 days.

The authors concluded that the immune-chromatography test assays for cTn-I prepared by AuNPs generated by plasma-liquid interaction exhibit higher detection sensitivity than those prepared by chemically reduced AuNPs detection. They believe that the microplasma-assisted synthesis of AuNPs have great potential for a variety of biomedical and therapeutic applications. The study was first published online on December 11, 2014, in the journal Plasma Processes and Polymers.

Related Links:

New York University Polytechnic School of Engineering
HyTest Ltd. 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.